Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality:a population-based study by Valachis, Antonis et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1007/s10549-016-3928-3
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Valachis, A., Garmo, H., Weinman, J., Fredriksson, I., Ahlgren, J., Sund, M., & Holmberg, L. (2016). Effect of
selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a
population-based study. Breast Cancer Research and Treatment, 1-11. 10.1007/s10549-016-3928-3
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
EPIDEMIOLOGY
Effect of selective serotonin reuptake inhibitors use on endocrine
therapy adherence and breast cancer mortality: a population-
based study
Antonis Valachis1 • Hans Garmo2 • John Weinman3 • Irma Fredriksson4 •
Johan Ahlgren5 • Malin Sund6 • Lars Holmberg2
Received: 8 June 2016 / Accepted: 20 July 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract The purpose of the study was to investigate
whether the concomitant use of selective serotonin reup-
take inhibitors (SSRI) with tamoxifen influences the risk of
death due to breast cancer, and we also investigated the
association between SSRI use and adherence to oral
endocrine therapy (ET). We analyzed data from BCBaSe
Sweden, which is a database created by the data linkage of
Registries from three different regions of Sweden. To
investigate the association between ET adherence and
SSRI use, we included all women who were diagnosed
with non-distant metastatic ER-positive invasive breast
cancer from July 2007 to July 2011 and had at least one
dispensed prescription of oral tamoxifen or aromatase
inhibitor. To investigate the role of concurrent adminis-
tration of SSRI and tamoxifen on breast cancer prognosis,
we performed a nested case–control study. In the adherence
cohort, 9104 women were included in the analyses.
Women who received SSRI, either before or after breast
cancer diagnosis, were at higher risk for low adherence to
ET. However, when the overlapping period between SSRI
use and ET was[50 %, no excess risk for low adherence
was observed. Non-adherence (\80 %) to ET was signifi-
cantly associated with worse breast cancer survival (OR
4.07; 95 % CI 3.27–5.06). In the case–control study, 445
cases and 11125 controls were included. The concomitant
administration of SSRI and tamoxifen did not influence
breast cancer survival, neither in short-term (OR 1.41;
95 % CI 0.74–2.68) nor in long-term SSRI users (OR 0.85;
95 % CI 0.35–2.08). Concomitant SSRI and tamoxifen use
does not seem to increase risk for death due to breast
cancer. Given the positive association between continuing
antidepressive pharmacotherapy for a longer period of time
and adherence to ET, it is essential to capture and treat
depression in breast cancer patients to secure adherence to
ET.
Keywords Breast cancer  SSRI  Adherence  Endocrine
therapy  Prognosis  Tamoxifen
Introduction
In patients with estrogen receptor (ER)-positive breast
cancer, adjuvant endocrine therapy, such as tamoxifen and
aromatase inhibitors (AIs), reduces the risk of breast cancer
recurrence and death [1, 2]. However, a considerable pro-
portion of patients discontinue their oral endocrine treat-
ment [3] despite the risk of jeopardizing their chances of
survival from breast cancer [4, 5]. There are many reasons
why people do not adhere to medical treatments [6] and a
significant one of these is depression [7], which is fairly
prevalent in patients with breast cancer [8]. There is some
evidence that the concomitant use of antidepressant and
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endocrine therapy in breast cancer is associated with a
poorer clinical outcome but the reasons for this have not
been fully explored [9, 10]. Two distinct, but not mutually
exclusive, explanations are possible for this, namely an
adherence effect and a drug interaction effect [4, 9].
Depression reduces the adherence to oral endocrine
therapy [11]. The association between depression, antide-
pressant therapy, and adherence to endocrine therapy is
complex, and several aspects need further investigation.
First, the role of antidepressant therapy before initiation of
endocrine therapy on adherence is unclear. Barron et al.
reported an association between antidepressant use before
breast cancer diagnosis and non-persistence to tamoxifen
therapy [12], but He et al. could not reveal a similar
association in a larger dataset [13]. Second, whether con-
tinuing antidepressant therapy after breast cancer diagnosis
affects adherence to endocrine therapy has not been stud-
ied. In addition, the effect of time to antidepressants ini-
tiation in respect to breast cancer diagnosis on adherence
has not been studied either.
A second explanation of the negative effect of the
concomitant use of antidepressants and oral endocrine
therapy is the potential risk for reduced activity of endo-
crine therapy due to drug interaction. The biologic ratio-
nale for this is that tamoxifen is a pro-drug that is catalyzed
to its active substance endoxifen predominantly by cyto-
chrome P450 isoenzyme 2D6 (CYP2D6) [14]; a cyto-
chrome that can be inhibited by the selective serotonin
reuptake inhibitors (SSRIs) antidepressants. If this inter-
action has a clinically relevant effect, the consequences for
clinical management are substantial: Tamoxifen has key
role as adjuvant endocrine therapy in a large proportion of
women with early breast cancer [1]; a considerable pro-
portion of breast cancer patients suffer from significant
depressive symptoms [8]; the current recommendation is to
use SSRIs as first-line treatment against depression
[15, 16].
Several studies have tried to investigate the clinical
effect of this potential interaction but have been hampered
by a limited number of events [17, 18], the use of a too
low cut-off for acceptable adherence rate [17], and the
lack of analyses on the effect of the length of time with
concomitant use of tamoxifen and SSRI [4, 19]. Two
studies could overcome these limitations, but their results
are contradictory. Kelly et al. showed an association
between a specific SSRI medication, paroxetine, and
increased risk of death from breast cancer [10]. However,
Haque et al. could not find an increased risk for breast
cancer recurrence in patients who concurrently used
tamoxifen and SSRI, including paroxetine [20]. As a
result, whether a clinically significant interaction between
SSRI and tamoxifen as it is supported by preclinical data
exists is still controversial.
We investigated whether the concomitant use of SSRI
and tamoxifen influences the risk of death due to breast
cancer. Since any such impact could be due to either drug
interaction or pattern of adherence, our secondary purpose
was to investigate the association between SSRI use, in
both the prediagnostic and the postdiagnostic period of
breast cancer, and adherence to oral endocrine therapy.
Patients and methods
Data source
The current study was based on data linkage of The
Regional Breast Cancer Clinical Quality Registers of the
Uppsala/O¨rebro, Stockholm-Gotland, and Northern regions
of Sweden. These registries represent approximately 60 %
of breast cancer patients in Sweden and contain informa-
tion on date of diagnosis, tumor characteristics, primary
treatment, and follow-up on all newly diagnosed breast
cancer patients with less than 5 % missing information, in
terms of diagnosis characteristics, of patients when vali-
dated against the National Swedish Cancer Register.
The Swedish Prescribed Drug Register contains infor-
mation on all the prescribed medications dispensed in
Swedish pharmacies since July 1, 2005. The database
provides information on each dispensed drug including
dates of dispensation, number of defined daily doses
(DDD), and classification of the drugs based on the ana-
tomic therapeutic chemical (ATC) system.
Individual-level information on socioeconomic and
demographic factors was obtained from the Longitudinal
integration database for health insurance and labor market
studies (LISA) managed by Statistics Sweden. This
nationwide database integrates existing data from labor
market-, educational-, and social-sector registers and con-
tains data from 1990 and onward on all individuals
16 years or older residing in Sweden and is updated yearly.
Finally, the Swedish Inpatient Register contains informa-
tion on hospital admission dates and diagnosis of diseases
and has had complete national coverage since 1987.
Information from the above registers was linked using a
ten-digit personal identifier numbers assigned for all per-
sons registered in Sweden.
Study population
We identified all women residing in the Uppsala/O¨rebro,
Stockholm-Gotland, and Northern healthcare regions of
Sweden who were diagnosed with ER-positive invasive
breast cancer without distant metastasis between January 1,
2004 and July 31, 2011 and had at least one dispensed
prescription of tamoxifen (ATC code: L02BA01) or AI
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(anastrozole, exemetastane, or letrozole; ATC code:
L02BG) after diagnosis. We included only patients who
were alive for at least 2.5 years after breast cancer diag-
nosis because of the risk to underestimate the adherence
rate in patients with early disease progression. In those
patients, the endocrine therapy has probably been stopped
by the treating physician, causing a falsely low adherence
rate. This patient subgroup is not interesting to be included
in a study investigating a potential drug interaction effect
because the breast cancer recurrence is most probably
related to an aggressive biology of the tumor.
Cohort for adherence study
For the adherence part of our study, we included patients
from our study population who were diagnosed with breast
cancer from 1/7/2007. Using this time period, we were able
to study the role of prediagnostic SSRI use on adherence
for a maximum of 2 years before diagnosis since the
Swedish Prescribed Drug Register was started 1/7/2005.
Nested case–control study
To investigate the role of concurrent administration of
SSRI and tamoxifen on breast cancer prognosis, we created
a nested case–control study. As cases we defined all
patients in our study population who died due to breast
cancer until the last date of follow-up (31/12/2014). Con-
trol patients (25 controls for each case) were selected using
the incidence density sampling after stratification for
region and year for diagnosis.
Adherence to oral endocrine treatment
Adherence to oral endocrine therapy was investigated
during the first 2 years after breast cancer diagnosis after a
run-in period of 6 months to minimize the risk for over-
estimation of non-adherence due to patients that were
treated with chemotherapy after breast cancer diagnosis.
Patterns of adherence were assessed based on tamoxifen
and AI-dispensed prescriptions recorded in the Swedish Pre-
scribed Drug Register. Adherence to oral endocrine treatment
was measured by calculating the medication possession ratio
(MPR) [21, 22]. MPR is defined as number of days of dis-
pensed prescribed supplies divided by the number of days in
study period 9 100 %. Actual prescribed daily dose (PDD)
for each patient was used for the MPR calculations.
Exposure to SSRI
Any prescription of SSRI during the study follow-up period
was identified, irrespective of the type of SSRI. However,
we excluded patients with serotonin and norepinephrine
reuptake inhibitor (SNRI) prescription to avoid inclusion of
patients treated with SNRI due to endocrine therapy-related
vasomotor symptoms (the SNRI venlafaxin is the only
antidepressant that is recommended against vasomotor
symptoms by the National Swedish breast cancer guideli-
nes [23]) rather than depression.
To investigate the effect of SSRI exposure on both
adherence and breast cancer survival, we divided the fol-
low-up time after breast cancer diagnosis into 3-month
periods. We then calculated the use of SSRI in each of
these 3-month periods.
The coverage period with SSRI use was\25 % if SSRI
was used in 0–1 of the 3-month periods; 25–50 % if SSRI
was used in 2–3 of the 3-month periods; 50–75 % if SSRI
was used in 4–5 of the 3-month periods;[75 % if SSRI
was used in 6–8 of the 3-month periods.
For the nested case–control part of the study, we also
divided the follow-up time into 3-month periods. We
defined as short-term SSRI users those patients that
received SSRI for 1–6 of the 3-month periods whereas
long-term SSRI users were defined as those who received
SSRI for C7 of the 3-month periods.
Endpoints
The endpoint in the nested case–control study was the odds
ratio (OR) of breast cancer death in relation to SSRI
exposure during study follow-up.
For the adherence cohort study, the endpoint was the
rate of adherence to oral endocrine therapy. We used a cut-
off value of 80 % to define patients with high versus low
adherence. A patient with MPR\80 % was defined as
patient with low adherence to oral endocrine therapy.
Covariates
Tumor-related characteristics (year of breast cancer diag-
nosis, tumor size, lymph node status, tumor grade, and pro-
gesterone-receptor status), treatment-related factors (type of
primary surgery, chemotherapy, and radiation therapy), and
patient-related factors (age at diagnosis) were obtained from
theRegionalQuality Registers. Comorbiditieswere assessed
by calculating the Charlson comorbidity index (CCI) based
on information on hospital admissions for diseases other than
breast cancer recorded in the Swedish Inpatient Register
since 10 years prior to the start of follow-up. From the LISA
database, we obtained information on socioeconomic factors
including education level.
Statistical analysis
Univariate and multivariable conditional logistic regression
were used to estimate OR and their accompanying 95 %
Breast Cancer Res Treat
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confidence intervals (CI) of breast cancer death in the
case–control study. ORs in the multivariable models were
adjusted for age, CCI, stage, grade, progesterone-receptor
status, type of surgery, radiotherapy, and chemotherapy.
Univariate and multivariable logistic regression was use
to estimate OR with associated 95 % CIs of the dichot-
omized outcome MPR\80 % (dependent variable) [24].
The multivariable models were adjusted for the same set of
covariates as in the conditional logistic regression above.
Results
We identified 18,432 women with ER-positive breast
cancer without distant metastasis treated with adjuvant
endocrine therapy during the study period (Jan 1, 2004–
July 31, 2011). In total, 445 women died due to breast
cancer by the end of follow-up.
The nested case–control study included 445 cases
(deaths due to breast cancer) and 11125 controls
(Fig. 1).The adherence cohort included 9104 women who
were diagnosed with non-metastatic ER-positive breast
cancer from July 2007 to July 31, 2011.
The study design with the different patient cohorts are
outlined in Fig. 2.
SSRI use and adherence
Of 9104 women in the adherence cohort, 731 (8 %) used
SSRI. Of those, 36 %had no history of SSRI use before breast
cancer diagnosis. The characteristics of the participants
included in the adherence cohort are presented in Table 1.
BCBaSe
Invasive Breast Cancer
(n=62 204)
Diagnosis between
1/1 2004 - 31/6 2011
(n=27 675)
Diagnosis before Jan 1 
2004 or after June 31 2011 
(n=34 529)
Metastatic disease
(n=804)
Non metastatic disease
(n=26 871)
Unknown ER-status
(n=5 486)
No ET treatment according 
to BCBaSe
(n=2 953)Eligible patients
(n=18 432)
To adherence study
(n=9 104)
Eligible to 
case-control study
(n=12 913)
n = 6 442
ER+
(n=21 385)
Fig. 1 Flow chart of study participants. ER Estrogen receptor, ET endocrine therapy
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SSRI use was associated with higher risk for low
adherence to oral endocrine therapy and this association
was significant in both patients who received SSRI prior to
breast cancer diagnosis (OR 1.33; 95 % CI 1.03–1.73) and
those with SSRI during the first months after breast cancer
diagnosis (OR 1.37; 95 % CI 1.01–1.85) (Table 2).
When we analyzed the association between SSRI use
and adherence based on the proportion of time on endo-
crine therapy that overlapped with SSRI use, we found that
there was a higher risk for low adherence in patients when
the overlapping period was\50 %, whereas in patients
with[50 % overlapping period this statistically significant
association disappeared (Table 2).
Considering the effect of non-adherence on breast can-
cer prognosis, we found that the dichotomized adherence
with an 80 % cut-off was significantly associated with
worse breast cancer survival when adjusted for other
prognostic factors (OR 4.07; 95 % CI 3.27–5.06).
Association between SSRI use during endocrine
treatment and prognosis
The characteristics of 445 cases and 11125 controls
included in the case–control study are presented in Table 3.
In the primary analysis including all the patients treated
with tamoxifen therapy irrespective of the adherence level,
patients with concomitant short-term SSRI use had worse
breast cancer survival than non-users (adjusted OR 1.58;
95 % CI 1.00–2.49), whereas no difference was observed
between long-term SSRI users and non-users (adjusted OR
0.68; 95 % CI 0.29–1.57) (Table 4).
To study a potential drug interaction, we restricted the
study population to women treated with tamoxifen
and C80 % adherence: neither short-term (OR 1.41; 95 %
CI 0.74–2.68) nor long-term SSRI (OR 0.85; 95 % CI
0.35–2.08) use was associated with breast cancer survival
(Table 4). When the same analysis was performed
A
ad
he
re
nc
e
st
ud
y 1/7 2005 31/12 20141/7 2007 30/6 2011
Start of 
Swedish 
Drug Registry
Last day of
follow up
Latest BC-date
for inclusion 
to adherence
study
Pre-diagnostic SSRI evaluation period
Post-diagnostic adherence evaluation period
6 months post diagnosis
Earliest BC-date 
for inclusion 
to adherence
study
Ca
se
-c
on
tr
ol
 s
tu
dy
1/1 2004
Earliest BC-date 
for inclusion 
to case-control
study
Time at risk before BC death (case)
Time at risk control
Period of adherence evaluation (case)
Period of adherence evaluation (control)
Period of survival amongst controls not used in study
Fig. 2 Description of study
design. SSRI Selective
serotonine receptor inhibitor,
BC breast cancer
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Table 1 Characteristics of
participants included in
adherence cohort
No SSRI prior to
BC diagnosis
(n = 8373)
SSRI prior to
BC diagnosis
(n = 731)
All
(n = 9104)
Year of cancer diagnosis, n (%)
2007–2009 4936 (59.0) 448 (61.3) 5384 (59.1)
2010–June 2011 3437 (41.0) 283 (38.7) 3720 (40.9)
Age at cancer diagnosis, n (%)
\40 303 (3.6) 31 (4.2) 334 (3.7)
40–49 1282 (15.3) 148 (20.2) 1430 (15.7)
50–59 1811 (21.6) 194 (26.5) 2005 (22.0)
60–69 2750 (32.8) 220 (30.1) 2970 (32.6)
70–79 1443 (17.2) 90 (12.3) 1533 (16.8)
80–89 723 (8.6) 47 (6.4) 770 (8.5)
90? 61 (0.7) 1 (0.1) 62 (0.7)
Tumor size, n (%)
B20 mm 5346 (63.8) 482 (65.9) 5828 (64.0)
20.1–50 mm 2648 (31.6) 217 (29.7) 2865 (31.5)
[50 mm 329 (3.9) 29 (4.0) 358 (3.9)
Missing data 50 (0.6) 3 (0.4) 53 (0.6)
N-stage, n (%)
N0 7286 (87.0) 639 (87.4) 7925 (87.0)
N? 1054 (12.6) 87 (11.9) 1141 (12.5)
NX/missing 33 (0.4) 5 (0.7) 38 (0.4)
M-stage, n (%)
M0 7286 (87.0) 630 (86.2) 7916 (87.0)
MX/missing 1087 (13.0) 101 (13.8) 1188 (13.0)
Grade, n (%)
Well 1824 (21.8) 171 (23.4) 1995 (21.9)
Moderately 4616 (55.1) 399 (54.6) 5015 (55.1)
Poorly 1747 (20.9) 147 (20.1) 1894 (20.8)
Missing 186 (2.2) 14 (1.9) 200 (2.2)
Treatment, n (%)
Breast conserving surgery 4888 (58.4) 420 (57.5) 5308 (58.3)
Mastectomy 3440 (41.1) 305 (41.7) 3745 (41.1)
Other surgery 25 (0.3) 4 (0.5) 29 (0.3)
Chemotherapy 2892 (34.5) 278 (38.0) 3170 (34.8)
Radiotherapy 6179 (73.8) 559 (76.5) 6738 (74.0)
CCI, n (%)
0 7278 (86.9) 623 (85.2) 7901 (86.8)
1 574 (6.9) 54 (7.4) 628 (6.9)
2 370 (4.4) 37 (5.1) 407 (4.5)
3? 151 (1.8) 17 (2.3) 168 (1.8)
Educational level, n (%)
High 2915 (34.8) 273 (37.3) 3188 (35.0)
Middle 3347 (40.0) 291 (39.8) 3638 (40.0)
Low 2025 (24.2) 160 (21.9) 2185 (24.0)
Missing 86 (1.0) 7 (1.0) 93 (1.0)
BC Breast cancer, CCI Charlson comorbidity index
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restricted to patients that received strong CYP2D6-in-
hibiting SSRIs (paroxetine, fluoxetine, and fluvoxamine),
no statistically significant association between SSRI use
and breast cancer survival was revealed (short-term SSRI
use, OR 2.00; 95 % CI 0.60–6.71; long-term SSRI use, OR
0.79; 95 % CI 0.18–3.44).
Discussion
In our population-based study, we found no association
between concomitant use of SSRI and tamoxifen and breast
cancer-specific survival. The lack of association was con-
sistent even when the analysis was restricted to patients
that used strong CYP2D6-inhibiting SSRIs or patients with
long-term co-administration of tamoxifen with SSRI.
However, poor adherence on endocrine therapy was clearly
associated with worse prognosis. Regarding the role of
SSRI on adherence to endocrine therapy, we found a
negative effect of both pre- and postdiagnostic SSRI use on
adherence with the exception of patients with SSRI use for
a longer period of time during study follow-up in whom the
adherence was comparable to those who have not been
treated with SSRI.
Early pharmacological studies revealed a decreased
endoxifen plasma concentration in patients who were poor
CYP2D6 metabolizers or those who received concomitant
CYP2D6 inhibitors, such as SSRIs [9, 25, 26]. This
observation raised the hypothesis that the concomitant
administration of tamoxifen and SSRIs could have a
Table 2 Association between non-adherence to endocrine therapy and SSRI use
Cases with
adherence\0.8
% Crude model Multivariate model
OR 95 % CI OR 95 % CI
SSRI usage prior to BC diagnosis
No SSRI 1307 15.0 1.00 Ref. 1.00 Ref.
SSRI 75 18.9 1.32 1.02–1.71 1.33 1.03–1.73
SSRI during 6-month period from BC diagnosis
No SSRI 1327 15.1 1.00 Ref. 1.00 Ref.
SSRI 55 19.0 1.33 0.98–1.79 1.37 1.01–1.85
SSRI during 6-month period from BC diagnosis without SSRI prior to BC diagnosis
No SSRI 1373 15.1 1.00 Ref. 1.00 Ref.
SSRI 9 23.7 1.74 0.82–3.68 1.76 0.83–3.76
SSRI usage prior to BC diagnosis but not during 6-month period after BC diagnosis
No SSRI 1353 15.1 1.00 Ref. 1.00 Ref.
SSRI 29 19.9 1.39 0.92–2.10 1.34 0.89–2.03
SSRI prior to 6 month from BC diagnosis
No SSRI 1298 15.0 1.00 Ref. 1.00 Ref.
SSRI 84 19.3 1.36 1.06–1.74 1.37 1.07–1.76
SSRI during month 7-31 from BC diagnosis
No SSRI 1233 14.7 1.00 Ref. 1.00 Ref.
SSRI\25 % of time 59 24.7 1.90 1.41–2.56 1.96 1.45–2.65
SSRI 25–50 % of time 27 20.5 1.49 0.97–2.28 1.48 0.97–2.28
SSRI 50–75 % of time 23 18.3 1.29 0.82–2.04 1.32 0.83–2.09
SSRI C0.75 % of time 40 17.1 1.19 0.85–1.69 1.17 0.83–1.66
SSRI during month 7-31 from BC diagnosis and history of SSRI
No SSRI 1233 14.7 1.00 Ref. 1.00 Ref.
SSRI\25 % of time, no usage prior to month 7 27 25.5 1.98 1.27–3.08 2.06 1.32–3.22
SSRI 25–50 % of time, no usage prior to month 7 19 22.1 1.64 0.98–2.74 1.66 0.99–2.78
SSRI 50–75 % of time , no usage prior to month 7 14 23.3 1.76 0.97–3.22 1.78 0.97–3.26
SSRI C75% of time, no usage prior to month 7 5 11.4 0.74 0.29–1.89 0.67 0.26–1.71
SSRI\50 % of time and usage prior to month 7 40 22.3 1.67 1.17–2.38 1.69 1.18–2.41
SSRI C50 % of time and usage prior to month 7 44 17.2 1.20 0.86–1.67 1.21 0.87–1.69
RR Relative risk, CI confidence interval, BC breast cancer
Breast Cancer Res Treat
123
detrimental effect on tamoxifen efficacy. However, the
results from two well-designed, large studies aimed to
investigate this hypothesis are contradictory [10, 20]. Kelly
et al. found that concomitant use of tamoxifen and parox-
etine increased the risk for death due to breast cancer.
However, the study did not include data on breast cancer
Table 3 Characteristics of
participants included in case–
control study
Case
(n = 445)
Control
(n = 11 125)
All
(n = 11 570)
Year of cancer diagnosis, n (%)
2004–2005 201 (45.2) 5025 (45.2) 5226 (45.2)
2006–2007 159 (35.7) 3975 (35.7) 4134 (35.7)
2008–2010 85 (19.1) 2125 (19.1) 2210 (19.1)
Age at cancer diagnosis, n (%)
\40 33 (7.4) 405 (3.6) 438 (3.8)
40–49 60 (13.5) 1851 (16.6) 1911 (16.5)
50–59 86 (19.3) 2860 (25.7) 2946 (25.5)
60–69 116 (26.1) 3508 (31.5) 3624 (31.3)
70–79 88 (19.8) 1824 (16.4) 1912 (16.5)
80–89 56 (12.6) 645 (5.8) 701 (6.1)
90? 6 (1.3) 32 (0.3) 38 (0.3)
TNM-stage, n (%)
I 91 (20.4) 6132 (55.1) 6223 (53.8)
II 264 (59.3) 4129 (37.1) 4393 (38.0)
III 52 (11.7) 243 (2.2) 295 (2.5)
IV 20 (4.5) 375 (3.4) 395 (3.4)
Missing data 18 (4.0) 246 (2.2) 264 (2.3)
PR-status, n (%)
PR- 134 (30.1) 2082 (18.7) 2216 (19.2)
PR? 302 (67.9) 8928 (80.3) 9230 (79.8)
Missing data 9 (2.0) 115 (1.0) 124 (1.1)
Grade, n (%)
1 26 (5.8) 2384 (21.4) 2410 (20.8)
2 228 (51.2) 6242 (56.1) 6470 (55.9)
3 161 (36.2) 2081 (18.7) 2242 (19.4)
Missing data 30 (6.7) 418 (3.8) 448 (3.9)
Treatment, n (%)
Local surgery 154 (34.6) 6637 (59.7) 6791 (58.7)
Mastectomy 277 (62.2) 4306 (38.7) 4583 (39.6)
No surgery/missing data 14 (3.1) 182 (1.6) 196 (1.7)
Chemotherapy 211 (47.4) 3305 (29.7) 3516 (30.4)
Radio therapy 310 (69.7) 8016 (72.1) 8326 (72.0)
CCI, n (%)
0 382 (85.8) 9925 (89.2) 10307 (89.1)
1 33 (7.4) 676 (6.1) 709 (6.1)
2 19 (4.3) 378 (3.4) 397 (3.4)
3? 11 (2.5) 146 (1.3) 157 (1.4)
Educational level, n (%)
High 124 (27.9) 3852 (34.6) 3976 (34.4)
Middle 174 (39.1) 4394 (39.5) 4568 (39.5)
Low 133 (29.9) 2765 (24.9) 2898 (25.0)
Missing data 14 (3.1) 114 (1.0) 128 (1.1)
PR Progesterone-receptor, CCI Charlson comorbidity index
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stage which could influence the results by including more
patients with late-stage disease in the paroxetine group. On
the other hand, Haque et al. could not find any association
between SSRI use during tamoxifen and breast cancer
recurrence, but no data on breast cancer survival were
presented.
Our results that poor adherence to endocrine therapy
was associated with worse prognosis are consistent with
prior studies [4, 5, 27] and further support the need to
develop interventions to improve adherence to endocrine
adjuvant therapy.
SSRI users had a worse adherence rate than non-SSRI
users. This observation was consistent irrespective of the
time of SSRI initiation (before or after breast cancer
diagnosis) indicating an association between SSRI use with
non-adherence to endocrine therapy. Considering the fact
that nearly 80 % of patients with SSRI prescription in
Sweden is due to depression [28], we hypothesize that there
is an association between depression and non-adherence to
endocrine therapy. Our results and hypothesis are in
accordance with a recent meta-analysis that showed that
patients with depressive symptoms had lower adherence to
endocrine therapy [11]. However, an association between
medical conditions other than depression in which SSRIs
are indicated, i.e., panic or anxiety disorders, and non-ad-
herence to endocrine therapy is also possible and further
research is needed. Based on the current evidence about the
role of depression on endocrine therapy adherence, it has
been hypothesized that effective management of depressive
symptoms in patients with cancer aids in promoting long-
term adherence to endocrine therapy. Although there is
some indirect evidence on the positive effect of psy-
chotherapy consultations as part of management against
depression on treatment adherence [29], no data exist on
the potential effect of pharmacotherapy for depression on
adherence. Interestingly, we found an improvement in
adherence in patients who received SSRI for a longer
period of time during study follow-up (SSRI use more than
50 % of time, namely more than 1 year). This suggests that
if the patients with breast cancer and depression receive
SSRI treatment as indicated (1–2 years after stabilization
of symptoms for the first episode; 5 years to lifetime for
subsequent episode [30–32]), the adherence to endocrine
therapy will be improved. This is the first study that sug-
gests a positive effect of antidepressive pharmacotherapy
on adherence to cancer therapy.
Our study has some limitations. First, prescription refill
does not guarantee that the patient has actually consumed
the prescribed medication; as a result, there is a risk for
underestimation of non-adherence. However, this under-
estimation is likely to be similar in SSRI users and non-
users. Second, we gathered data on comorbidities from
inpatient registry and there is a considerably risk that some
common comorbidities might be missed. However, the
adjustment of our analyses with the CCI measure, which is
a measure of more severe comorbid conditions, did not
influence the results, indicating that comorbidities do not
seem to affect the results. Third, we had no data on the
CYP2D6 genotype in our cohort. However, a recent meta-
analysis concluded that there is no evidence that different
CYP2D6 polymorphisms affect breast cancer prognosis in
breast cancer patients treated with tamoxifen [33]. Another
potential limitation of our study is the lack of data on the
indication of SSRI use in our cohort. Some SSRIs may
have been used for the treatment of hot flashes related to
endocrine therapy. However, the most evidence-based and
commonly used antidepressant for this indication is ven-
lafaxine, which is the only recommended antidepressant
against hot flashes by the national swedish breast cancer
guidelines [23], and therefore, we excluded this drug from
our analyses to minimize the risk of bias. Moreover, ven-
lafaxine is a non-significant inhibitor of CYP2D6 [34].
Furthermore, our study concentrated on SSRIs and did not
take into account other antidepressants. The proportion of
women receiving antidepressants other than SSRIs is
considered low in our cohort because of the recommen-
dation to use SSRI as first-line therapy against depression
in Sweden [15]. Finally, our analyses did not take into
account the concomitant use of other strong CYP2D6
inhibitors. However, the clinical indication for the use of
other strong CYP2D6 inhibitors (bupropion, quinidine) is
limited and as result the number of patients treated with
these medications is expected to be low. In addition, dif-
ferences in use of other strong CYP2D6 inhibitors by SSRI
usage are not expected in our cohort.
In conclusion, we could not find a negative effect of
SSRI use during tamoxifen treatment with respect to risk of
breast cancer death even in subgroups of patients that the
biological rationale behind the hypothesis was supposed to
be stronger (use of strong CYP2D6-inhibitors or use of
SSRIs for a long period concomitant with tamoxifen). We
suggest that, in breast cancer patients who are successfully
Table 4 Odds ratios for breast cancer death by exposure of SSRI
Crude model Multivariate model
Exposure OR 95% CI OR 95% CI
Overall study population
No SSRI 1.00 Ref. 1.00 Ref.
Short-term SSRI users 1.25 0.81–1.94 1.58 1.00–2.49
Long-term SSRI users 0.58 0.26–1.31 0.68 0.29–1.57
Women with adherence[80%
No SSRI 1.00 Ref. 1.00 Ref.
Short-term SSRI users 1.18 0.64–2.20 1.41 0.74–2.68
Long-term SSRI users 0.79 0.35–1.81 0.85 0.35–2.08
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treated with SSRIs and are planning to start with tamox-
ifen, there is no need to change SSRI therapy. However,
physicians should discuss other treatment options instead
of strong CYP2D6-inhibiting SSRIs with their patients
with breast cancer on tamoxifen that need to start with
antidepressive therapy, given the biological rationale and
the results from one previous well-designed epidemiolog-
ical study [20]. Finally, depressive symptoms should be
captured early in breast cancer patients and adequate
pharmacotherapy should be initiated with support to
facilitate adherence to both antidepressants and tamoxifen.
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